Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology.
ACTH
Addison’s disease
bilateral adrenalectomy
congenital adrenal hyperplasia
cortisol
immunophenotype
primary adrenal insufficiency
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
08
2023
accepted:
27
10
2023
medline:
5
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Patients with primary adrenal insufficiency (PAI) suffer from increased risk of infection, adrenal crises and have a higher mortality rate. Such dismal outcomes have been inferred to immune cell dysregulation because of unphysiological cortisol replacement. As the immune landscape of patients with different types of PAI has not been systematically explored, we set out to immunophenotype PAI patients with different causes of glucocorticoid (GC) deficiency. This cross-sectional single center study includes 28 patients with congenital adrenal hyperplasia (CAH), 27 after bilateral adrenalectomy due to Cushing's syndrome (BADx), 21 with Addison's disease (AD) and 52 healthy controls. All patients with PAI were on a stable GC replacement regimen with a median dose of 25 mg hydrocortisone per day. Peripheral blood mononuclear cells were isolated from heparinized blood samples. Immune cell subsets were analyzed using multicolor flow cytometry after four-hour stimulation with phorbol myristate acetate and ionomycin. Natural killer (NK-) cell cytotoxicity and clock gene expression were investigated. The percentage of T helper cell subsets was downregulated in AD patients (Th1 p = 0.0024, Th2 p = 0.0157, Th17 p < 0.0001) compared to controls. Cytotoxic T cell subsets were reduced in AD (Tc1 p = 0.0075, Tc2 p = 0.0154) and CAH patients (Tc1 p = 0.0055, Tc2 p = 0.0012) compared to controls. NKCC was reduced in all subsets of PAI patients, with smallest changes in CAH. Degranulation marker CD107a expression was upregulated in BADx and AD, not in CAH patients compared to controls (BADx p < 0.0001; AD p = 0.0002). In contrast to NK cell activating receptors, NK cell inhibiting receptor CD94 was upregulated in BADx and AD, but not in CAH patients (p < 0.0001). Although modulation in clock gene expression could be confirmed in our patient subgroups, major interindividual-intergroup dissimilarities were not detected. In patients with different etiologies of PAI, distinct differences in T and NK cell-phenotypes became apparent despite the use of same GC preparation and dose. Our results highlight unsuspected differences in immune cell composition and function in PAI patients of different causes and suggest disease-specific alterations that might necessitate disease-specific treatment.
Identifiants
pubmed: 38045693
doi: 10.3389/fimmu.2023.1275828
pmc: PMC10690587
doi:
Substances chimiques
Glucocorticoids
0
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1275828Informations de copyright
Copyright © 2023 Nowotny, Marchant Seiter, Ju, Gottschlich, Schneider, Zopp, Vogel, Tschaidse, Auer, Lottspeich, Kobold, Rothenfusser, Beuschlein, Reincke, Braun and Reisch.
Déclaration de conflit d'intérêts
SK has received honoraria from TCR2 Inc, Novartis, BMS and GSK. SK is inventor of several patents in the field of immuno-oncology. SK received license fees from TCR2 Inc and Carina Biotech. A.G. received research support from Tabby Therapeutics for work unrelated to the manuscript. SK received research support from TCR2 Inc., Plectonic GmbH and Arcus Bioscience for work unrelated to the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Eur J Immunol. 2004 Nov;34(11):3028-38
pubmed: 15368269
Clin Med (Lond). 2017 Jun;17(3):258-262
pubmed: 28572228
J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31
pubmed: 26222757
Front Endocrinol (Lausanne). 2021 Aug 19;12:701263
pubmed: 34489864
Eur J Endocrinol. 2021 Mar;184(3):353-363
pubmed: 33444228
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32436951
Immunotherapy. 2011 Sep;3(9):1075-86
pubmed: 21913830
J Clin Endocrinol Metab. 2014 Dec;99(12):E2715-21
pubmed: 25279502
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4509-e4519
pubmed: 34165575
J Clin Endocrinol Metab. 2006 Dec;91(12):4849-53
pubmed: 16968806
Ann Endocrinol (Paris). 2017 Dec;78(6):490-494
pubmed: 29174931
Eur J Endocrinol. 2016 May;174(5):601-9
pubmed: 26865584
J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62
pubmed: 18413427
Leukemia. 2015 Apr;29(4):828-38
pubmed: 25322685
J Clin Invest. 1986 May;77(5):1501-6
pubmed: 2422208
Autoimmun Rev. 2005 Jul;4(6):351-63
pubmed: 16081026
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2375-2384
pubmed: 30715394
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
Eur J Endocrinol. 2012 Jul;167(1):35-42
pubmed: 22513882
Ann N Y Acad Sci. 2004 Jun;1024:138-46
pubmed: 15265778
Eur J Endocrinol. 2017 Apr;176(4):471-480
pubmed: 28223394
Brain Behav Immun. 2011 Feb;25(2):239-49
pubmed: 20656012
Lancet Diabetes Endocrinol. 2018 Mar;6(3):173-185
pubmed: 29229498
N Engl J Med. 2019 Aug 29;381(9):852-861
pubmed: 31461595
Nat Rev Immunol. 2021 Apr;21(4):233-243
pubmed: 33149283
Eur J Endocrinol. 2022 Oct 13;187(5):719-731
pubmed: 36102827
Int J Endocrinol. 2018 Dec 18;2018:1464967
pubmed: 30662460
J Endocrinol Invest. 2011 Dec;34(11):831-4
pubmed: 21169727
Endocrine. 2021 Mar;71(3):586-594
pubmed: 33661460
Eur J Endocrinol. 2010 Mar;162(3):597-602
pubmed: 19955259
J Exp Med. 2004 May 3;199(9):1285-91
pubmed: 15117972
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31665382
Inflammopharmacology. 2018 Oct;26(5):1331-1338
pubmed: 29159714
Biomedicines. 2021 Oct 05;9(10):
pubmed: 34680514
FASEB J. 2007 Apr;21(4):1177-88
pubmed: 17215482
Eur J Endocrinol. 2015 Apr;172(4):R143-9
pubmed: 25722097
Lancet Diabetes Endocrinol. 2016 Jul;4(7):611-29
pubmed: 27177728
Horm Metab Res. 2018 Apr;50(4):290-295
pubmed: 29458220
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Nat Rev Immunol. 2015 May;15(5):295-307
pubmed: 25848755
J Endocrinol Invest. 2005 Jul-Aug;28(7):632-7
pubmed: 16218046
J Clin Endocrinol Metab. 2020 Feb 1;105(2):
pubmed: 31532828
Horm Metab Res. 2014 Jan;46(1):48-53
pubmed: 23918683
J Clin Endocrinol Metab. 2013 Oct;98(10):3939-48
pubmed: 23956347
Curr Opin HIV AIDS. 2010 Mar;5(2):120-7
pubmed: 20543588
J Immunol Res. 2019 Apr 14;2019:1356540
pubmed: 31111075
J Clin Endocrinol Metab. 1996 Jun;81(6):2303-6
pubmed: 8964868
Eur J Endocrinol. 2013 Mar 15;168(4):609-14
pubmed: 23384710
Cell Mol Immunol. 2020 Jul;17(7):705-711
pubmed: 32503998
Steroids. 2014 Dec;91:38-45
pubmed: 24769248
Endocrinology. 2015 Oct;156(10):3504-10
pubmed: 26207344
Endocrine. 2019 Apr;64(1):157-168
pubmed: 30467627
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044
J Neuroendocrinol. 2022 Aug;34(8):e13113
pubmed: 35312199
J Clin Endocrinol Metab. 2018 Aug 1;103(8):2998-3009
pubmed: 29846607
Eur J Endocrinol. 2015 Mar;172(3):R115-24
pubmed: 25288693
Br J Pharmacol. 2022 Jul;179(13):3135-3151
pubmed: 34935128